OBJECTIVES/GOALS: We leverage the disparate incidence of Ewing sarcoma (ES) between European (EUR) and African (AFR) ancestry to study ES tumorigenesis in iPSC-derived cells from donors with a range of AFR ancestry via functional / molecular profiling. Integrated multi-omics analysis furthers explore local regulatory networks in pursuit of novel drug targets of ES. METHODS/STUDY POPULATION: In our pilot, eight induced pluripotent stem cell lines were obtained, differentiated into neural crest cells, and then transduced with a lentivirus expressing GFP-2A-EWS/FLI1. We compared wild type (WT) to EWS-FLI1-induced cells and then compared cell survival, gene expression, and EWS-FLI1 binding differences at varying levels of EUR / AFR ancestry admixture. We will build on this pilot data by expanding the number of cell lines and measuring chromatin state. Subsequently we will refine our understanding of the relationships between local ancestry, epigenetic and gene expression changes, and phenotype in tumor progression via integration of multi-omics datasets. Our systems genomics approach will utilize directed local regulatory networks in a Bayesian structure learning framework. RESULTS/ANTICIPATED RESULTS: Induction by EWS-FLI1 resulted in gene expression changes enriched in known ES gene sets. Higher %EUR ancestry correlated with prolonged maintenance of EWS-FLI1. We identified thousands of ancestry-linked changes to gene expression and EWS-FLI1 binding. Eighty of these genes are both differentially expressed and differentially bound based on AFR ancestry admixture level and may be some of the early critical targets that initiate the cascade of molecular changes in ES. We will identify novel drug targets, with potential cross functional use of known drugs. Once we have developed directed local regulatory networks, we will use them to test in silico potential perturbations due to small molecules or novel drugs and predict expression changes. DISCUSSION/SIGNIFICANCE: With a limited number of cell lines, we identify 80 ancestry-linked candidate loci for functional validation through genome engineering. As EWS-FLI1 itself has proven elusive to direct targeting, studying its immediate downstream effects has the potential for establishing new druggable biologic pathways for treatment of ES.

Ontology deals with questions concerning what things exist, and how such things may be associated according to similarities and differences and related within a hierarchy. Ontology provides a rigorous way to develop a general definition of a mineral species. Properties may be divided into two principal groups: an intrinsic property is characteristic of the object and is independent of anything else; an extrinsic property depends on the relation between the object and other things. A universal is an entity that is common to all objects in a set. Here the objects are mineral samples, each entity is a specific property of these minerals, and the set of objects is all mineral samples of that mineral species. The key intrinsic properties of a mineral species are its name, its end-member formula and Z (the number of formula units in the unit cell), its space group and the bond topology of the end-member structure. These are also universals as they are common to all mineral samples belonging to that mineral species. An archetype is a pure form which embodies the fundamental characteristics of an object. Thus the archetype of a mineral species embodies the above set of universals. Real mineral samples of this mineral species are imperfect copies of that archetype, with a range of chemical composition defined by the boundaries between end-member formulae of this and other end members of the same bond topology. The result is a formal definition of a mineral species: A specific mineral species is the set of imperfect copies of the corresponding archetype and is defined by the following set of universals: name, end-member formula and Z, space group, and bond topology of the end-member structure, with the range of chemical composition limited by the compositional boundaries between end members with the same bond topology.

Native tungsten (IMA2011-004), W, is officially described as a new mineral from gold placers in the Bol'shaya Pol'ya river valley, Prepolar Urals, Russia, associated with yttriaite-(Y) and from quartz veins in the Mt Neroyka rock-crystal field, Ust–Puiva, Tyumenskaya Oblast', Russia. Tungsten forms polycrystalline grains and masses, and rarely cubo-octahedra. It is silver white to steel grey in colour, with metallic lustre and grey streak. The calculated density is 19.226 g/cm3. The Vickers hardness (VHN25) is 571.45 kg/mm2. In plane polarised light, tungsten is white with a pale-yellow tint and optically isotropic. Electron microprobe analyses of Bol'shaya Pol'ya river valley material provided W 99.27, Mo 0.06, Mn 0.04, Fe 0.01, total 99.38 wt.%. The five strongest powder X-ray diffraction lines are [dobs Å(I)(hkl)]: 2.2422(100)(110), 1.5835(25)(200), 1.2929(48)(211), 1.0010(23)(310) and 0.8457(24)(321). Tungsten is cubic, Im$\bar{3}$m, a = 3.1648(4) Å, V = 31.69(4) Å3 and Z = 2. Some additional occurrences of native tungsten and technogenic tungsten found in Nature are also described.

Treatment resistant schizophrenia (TRS) is one of the most disabling of psychiatric disorders, affecting about 1/3 of patients. First-line treatments include both atypical and typical antipsychotics. The original atypical, clozapine, is a final option, and although it has been shown to be the only effective treatment for TRS, many patients do not respond well to clozapine. Clozapine use is related to adverse events, most notably agranulocytosis, a potentially fatal blood disorder which affects about 1% of those prescribed clozapine and requires regular blood monitoring. This as a barrier to prescription and there is a long delay in access for TRS patients, of five or more years, from first antipsychotic prescription. Better tools to predict treatment resistance and to identify risk of adverse events would allow faster and safer access to clozapine for patients who are likely to benefit from it. The CRESTAR project (www.crestar-project.eu) is a European Framework 7 collaborative project that aims to develop tools to predict i) treatment response, particularly patients who are less likely to respond to usual antipsychotics, indicating treatment with clozapine as early as possible, ii) patients who are at high or low risk of adverse events and side effects, iii) extreme TRS patients so that they can be stratified in clinical trials for novel treatments. CRESTAR has addressed these questions by examining genome-wide association data, genome sequence, epigenetic biomarkers and epidemiological data in European patient cohorts characterized for treatment response, and adverse drug reaction using data from clozapine therapeutic drug monitoring and linked National population medical and pharmacy databases, to identify predictive factors. In parallel CRESTAR will perform health economic research on potential benefits, and ethics and patient-centred research with stakeholders.

The mineral ‘oboyerite’, first described in 1979 from the Grand Central mine, Tombstone, Cochise County, Arizona, USA, has been re-examined. The type specimen from the Natural History Museum, London and a specimen from the Natural History Museum of Los Angeles County (traceable to S. A Williams, who first described ‘oboyerite’) were analysed in this study. The discreditation of ‘oboyerite’ as a valid mineral species has been approved by the Commission on New Minerals, Nomenclature and Classification of the International Mineralogical Association (Proposal 19-D). Single-crystal X-ray diffraction, powder X-ray diffraction, electron probe microanalysis and scanning electron microscopy were all employed to show that ‘oboyerite’ is formed of at least two distinct phases, including the lead–tellurium oxysalt minerals ottoite and plumbotellurite. During the course of the discreditation, plumbotellurite was confirmed to be identical to the synthetic compound α-Pb2+Te4+O3. Previously, in some mineralogical literature plumbotellurite was described as orthorhombic with no known crystal structure.

Clinical Enterobacteriacae isolates with a colistin minimum inhibitory concentration (MIC) ≥4 mg/L from a United States hospital were screened for the mcr-1 gene using real-time polymerase chain reaction (RT-PCR) and confirmed by whole-genome sequencing. Four colistin-resistant Escherichia coli isolates contained mcr-1. Two isolates belonged to the same sequence type (ST-632). All subjects had prior international travel and antimicrobial exposure.

Omsite (IMA 2012-025) is a new mineral from the Correc d'en Llinassos, Oms, Pyrénées-Orientales Department, France. It occurs as bright yellow to amber yellow discoidal tablets, flattened on {001}, which form rosettes typically 50–100 μm in diameter. Omsite generally crystallizes on siderite without associated supergene minerals; it occurs less commonly with glaukosphaerite. Crystals have a vitreous to resinous lustre, and are transparent to translucent. Omsite is not fluorescent in either short-wave or long-wave ultraviolet light. It has an estimated hardness of 3 on the Mohs' scale, is brittle with an irregular fracture, and has one poor cleavage on {001}. The calculated density is 3.378 g cm–3. Crystals are uniaxial (–), with indices of refraction of ω = 1.728(3) and ε = 1.66(1), measured in white light. Pleochroism is ω = orange-yellow, ε = pale orange-yellow; ω > ε. The empirical formula [based on 12 (OH + Cl) p.f.u.] is (Ni1.0992+Cu0.6652+Mg0.107Fe0.0453+)Σ 1.916Fe1.0003+(Sb0.9475+As0.072Na0.029)Σ1.048OH11.967Cl0.033. Omsite crystallizes in space group P, with unit-cell parameters a = 5.3506(8), c = 19.5802(15) Å, V = 485.46(10) Å3 and Z = 2 determined by single crystal X-ray diffraction. The five strongest lines in the X-ray powder diffraction pattern [d in Å, (Irel), (hkl)] are as follows: 4.901, (100), (004); 4.575, (83), (011); 2.3539, (81), (11); 1.8079, (48), (11); 3.781, (34), (103). The crystal structure was solved to R1 = 0.0896 for 356 observed reflections [Fo>4σFo] and 0.1018 for all the 469 unique reflections. Omsite is a layered double hydroxide (LDH) mineral, with a topology consistent with members of the hydrotalcite supergroup and cualstibite group.

A single crystal of natrojarosite, NaFe3(SO4)2(OH)6, was investigated by single-crystal X-ray diffraction at high-pressure conditions (up to 8.8 GPa) using a diamond-anvil cell. The unit-cell parameters were determined at 11 different pressures and no indications of a phase transition were found up to the maximum pressure reached. The volume and axial moduli were fitted to a third-order Birch–Murnaghan equation-of-state which gave the following values: V0 = 769.6(2) Å3, KT0 = 50.6(9) GPa, K' = 9.9(4); a = 7.3172(6) Å, KT0 = 104(2), K' = 7.6(9); c = 16.5965(20) Å, KT0 = 24.6(4) and K' = 7.1(2). The crystal structure of natrojarosite was refined at seven different pressures up to 8.779(11) GPa [a = 7.3170(4), c = 16.5955(5) Å and V = 769.46(9) Å3 in Rm at 0.00010(1) GPa and a = 7.1594(8), c = 15.6003(17) Å and V = 692.49(8) Å3 at 8.779(11) GPa]. The structural analysis shows that the 12-fold Na polyhedron accommodates most of the deformation by a large volume decrease (14%) and strong polyhedral distortion (63%). Our results indicate that natrojarosite has the most compressible structure of the supergroup studied so far, and has a very strong axial anisotropy.

The type specimen of liskeardite, (Al, Fe)3AsO4(OH)6·5H2O, from the Marke Valley Mine, Liskeard District, Cornwall, has been reinvestigated. The revised composition from electron microprobe analyses and structure refinement is [Al29.2Fe2.8(AsO4)18(OH)42(H2O)22]·52H2O. The crystal structure was determined using synchrotron data collected on a 2 μm diameter fibre at 100 K. Liskeardite has monoclinic symmetry, space group I2, with the unit-cell parameters a = 24.576(5), b = 7.754(2) Å, c = 24.641(5) Å, and β = 90.19(1)º. The structure was refined to R = 0.059 for 9769 reflections with I > 3σ(I). It is of an open framework type in which intersecting polyhedral slabs parallel to (101) and (10) form 17.4 Å × 17.4 Å channels along [010], with water molecules occupying the channels. Small amounts (<1 wt.%) of Na, K and Cu are probably adsorbed at the channel walls The framework comprises columns of pharmacoalumite-type, intergrown with chiral chains of six cis edge-shared octahedra. It can be described in terms of cubic close packing, with vacancies at both the anion and cation sites. The compositional and structural relationships between liskeardite and pharmacoalumite are discussed and a possible mechanism for liskeardite formation is presented.

The crystal structure of deliensite, Fe[(UO2)2(SO4)2(OH)2](H2O)7, was solved by direct methods and refined to R 1 = 6.24% for 5211 unique observed reflections [I obs > 3σ(I)],on a crystal that was found to consist of rotational and inversion (merohedral) twins, from Jeroným mine, Abertamy in the Czech Republic. The presence of four twin domains was taken into account in the refinement. The structure is orthorhombic, space group Pnn2, with unit-cellparameters a = 15.8514(9), b = 16.2478(7), c = 6.8943(3) Å, V = 1775.6(1) Å3 and Z = 4. The crystal structure of deliensite contains uranyl-sulfate sheets with a phosphuranylite topology, consisting of dimers of edge-sharing uranylpentagonal bipyramids linked by corner-sharing with sulfate tetrahedra. The sheets lie in the (100) plane and are decorated by [Fe2+O(H2O)5] octahedra; two weakly bonded H2O molecules are present in the interlayer. The [Fe2+O(H2O)5]octahedron is linked directly to the sheet via the uranyl oxygen atom. Adjacent sheets are linked by hydrogen bonds only. The sheet topology and geometrical isomerism is discussed and a comparison of the composition obtained from electron-probe microanalysis, powder-diffraction data, Ramanand infrared spectra of deliensite samples from Mas d'Alary, Lodève, France; L'Ecarpière mine, Gétigné, France; and several localities at Jáchymov, Western Bohemia, Czech Republic is made.